Arvinas (ARVN) Operating Income (2017 - 2026)
Arvinas (ARVN) posted quarterly Operating Income of -$63.8 million for Q1 2026, down 189.36% year-over-year from $71.4 million in Q1 2025, and up 14.48% quarter-over-quarter from -$74.6 million in Q4 2025.
Arvinas (ARVN) Operating Income (2017 - 2026) Analysis & Trends
Arvinas' Operating Income history runs 10 years deep, the most recent figure standing at -$63.8 million for Q1 2026.
- In Q1 2026, Operating Income fell 189.36% year-over-year to -$63.8 million; the TTM figure through Mar 2026 stood at -$253.7 million (down 165.38% YoY), while the FY2025 annual figure was -$118.5 million, up 52.64% from the prior year.
- Operating Income for Q1 2026 stood at -$63.8 million, up from -$74.6 million in the prior quarter.
- The five-year high for Operating Income was $71.4 million in Q1 2025, with the low at -$165.3 million in Q4 2023.
- The 5-year median for Operating Income is -$65.8 million (2022), against an average of -$64.6 million.
- The sharpest annual moves came in 2025 and 2026: Operating Income jumped 185.71% in 2025, then sank 189.36% in 2026.
- Arvinas' Operating Income stood at -$75.6 million in 2022, then tumbled by 118.65% to -$165.3 million in 2023, then surged by 64.79% to -$58.2 million in 2024, then retreated by 28.18% to -$74.6 million in 2025, then gained by 14.48% to -$63.8 million in 2026.
- Business Quant data shows ARVN's Operating Income at -$63.8 million in Q1 2026, -$74.6 million in Q4 2025, and -$43.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 164.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.10 Mn |
| Mar 31, 2026 | -63.80 Mn |
| Dec 31, 2025 | -74.60 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -71.50 Mn |
| Mar 31, 2025 | 71.40 Mn |
| Dec 31, 2024 | -58.20 Mn |
| Sep 30, 2024 | -60.30 Mn |
| Jun 30, 2024 | -48.50 Mn |
| Mar 31, 2024 | -83.30 Mn |
| Dec 31, 2023 | -165.30 Mn |
| Sep 30, 2023 | -73.90 Mn |
| Jun 30, 2023 | -74.60 Mn |
| Mar 31, 2023 | -87.70 Mn |
| Dec 31, 2022 | -75.60 Mn |
| Sep 30, 2022 | -64.30 Mn |
| Jun 30, 2022 | -65.80 Mn |
| Mar 31, 2022 | -57.70 Mn |
| Dec 31, 2021 | -47.50 Mn |
| Sep 30, 2021 | -47.30 Mn |